RPL17 and melanoma: By contrast, pre-exposure to DAC/IL-33 unleashed the anti-tumor response to PD-1 mAb in melanoma-bearing mice, as shown by significant tumor growth delay and ameliorated survival with respect to DAC/IL-33 and control (Fig. 3B, C).